China Pharma Holdings (CPHI) Retained Earnings (2010 - 2026)

China Pharma Holdings has reported Retained Earnings for 17 years, with the latest figure at -$48.4 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 7.91% year-over-year to -$48.4 million; the trailing twelve-month figure through Mar 2026 stood at -$48.4 million (down 7.91% YoY), and the FY2025 full-year result was $11.6 million, up 2.32% from the prior year.
• Retained Earnings for Q1 2026 stood at -$48.4 million, down from $11.6 million in the prior quarter.
• The five-year high for Retained Earnings was $12.6 million in Q1 2022, with the low at -$48.4 million in Q1 2026.
• Historically, Retained Earnings has averaged -$16.5 million across 5 years, with a median of -$34.2 million in 2022.
• Annual changes were most pronounced in 2022 — Retained Earnings jumped 142.61% — and 2025, when it tumbled 497.89%.
• China Pharma Holdings' Retained Earnings stood at $11.6 million in 2022, then fell by 1.05% to $11.5 million in 2023, then retreated by 1.16% to $11.3 million in 2024, then increased by 2.32% to $11.6 million in 2025, then tumbled by 517.5% to -$48.4 million in 2026.
• The last three Retained Earnings figures came in at -$48.4 million (Q1 2026), $11.6 million (Q4 2025), and -$46.0 million (Q3 2025), per Business Quant data.